- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00856024
ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632) (ATHENAS)
4. juni 2015 opdateret af: Merck Sharp & Dohme LLC
ATHENAS - Retrospective Analysis of Compliance to Treatment of Chronic Hepatitis C With Pegylated Interferon Alpha 2b Associated to Ribavirin Until Week 12 and Correlation With Virological Response in Brazil Health Centers
This is a Phase 4, retrospective and observational, multicenter, national (Brazil), open, noncomparative, and nonrandomized study, which does not have visits.
This study will be conducted in accordance to Good Clinical Practices.
The procedure will be the review of medical records of patients who have already completed 12 weeks of treatment of chronic hepatitis C with peginterferon alfa-2b and ribavirin.
This review will take place after the subjects have signed the informed consent form authorizing collection of these data.
The collection of data for virological response after Week 12 will be collected prospectively through the review of medical records after the subjects have completed their entire treatment and follow-up period.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a Phase 4, retrospective and observational, multicenter, national (Brazil), open, noncomparative, and nonrandomized study, which does not have visits.
This study will be conducted in accordance to Good Clinical Practices.
The procedure will be the review of medical records of patients who have already completed 12 weeks of treatment of chronic hepatitis C with peginterferon alfa-2b and ribavirin.
This review will take place after the subjects have signed the informed consent form authorizing collection of these data.
The physician will be filling out the case report form with the information contained in the medical record.
Any dose reduction and/or doses not taken during this period will be reported through the case report form.
The collection of data for virological response after Week 12 (such as virological response at the end of treatment and sustained virological response after follow-up period) will be collected prospectively through the review of medical records after the subjects have completed their entire treatment and follow-up period.
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
902
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Patients with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin.
Patients will come from approximately 65 Brazilian sites and should satisfy all inclusion criteria and none of the exclusion criteria.
Beskrivelse
Inclusion Criteria:
- Must have confirmed his/her willingness in participating in this study, after having been informed of all aspects that are pertinent to his/her decision to participate, by signing and dating the informed consent form (ICF) approved by the Institutional Review Board / Independent Ethics Committee on Research (IRB/IEC).
- Adult patients who are 18 years old or above.
- Must have diagnosis of chronic hepatitis C confirmed through positive qualitative or quantitative PCR (polymerase chain reaction) performed prior to initiation of the patient's treatment. This result shall be documented in the patient's records.
- Must have completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin.
- Patients who started treatment for chronic hepatitis C from the year 2008 or later.
Exclusion Criteria:
- Does not confirm his/her willing in participating in this study or refuses to sign the informed consent form.
- Did not start the treatment with peginterferon alfa-2b and ribavirin.
- Patients who have less than 12 weeks of treatment with peginterferon alfa-2b and ribavirin.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
Group 1: Naïve patients
Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had not been treated with peginterferon alfa-2b.
|
PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg.
The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
Andre navne:
Ribavirin 250 mg.
The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
Andre navne:
|
Group 2: Re-treatment
Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had been considered nonresponders or relapsing to prior treatment for chronic hepatitis C.
|
PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg.
The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
Andre navne:
Ribavirin 250 mg.
The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
Andre navne:
|
Group 3: HIV/HCV co-infected patients
Patients, from Brazil, with confirmed chronic hepatitis C and infected with Humman Immunodeficiency Virus (HIV) who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin.
|
PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg.
The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
Andre navne:
Ribavirin 250 mg.
The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percent of Participants Who Were Compliant to Treatment in the First 12 Weeks
Tidsramme: First 12 weeks of treatment
|
The participant was considered compliant if he/she had administered 80% of the doses of pegylated interferon alpha 2b and 80% of the doses of ribavirin that were prescribed by the physician in the first 12 weeks of treatment.
|
First 12 weeks of treatment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percent of Participants Who Achieved Rapid Virologic Response (RVR)
Tidsramme: Week 4
|
RVR was defined as HCV RNA negative after 4 weeks of treatment.
|
Week 4
|
Percent of Participants Who Achieved Early Virologic Response (EVR)
Tidsramme: Week 12
|
EVR was defined as HCV RNA negative after 12 weeks of treatment.
|
Week 12
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juli 2008
Primær færdiggørelse (Faktiske)
1. oktober 2010
Studieafslutning (Faktiske)
1. oktober 2010
Datoer for studieregistrering
Først indsendt
4. marts 2009
Først indsendt, der opfyldte QC-kriterier
4. marts 2009
Først opslået (Skøn)
5. marts 2009
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
1. juli 2015
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
4. juni 2015
Sidst verificeret
1. juni 2015
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Leversygdomme
- Flaviviridae infektioner
- Hepatitis, viral, menneskelig
- Enterovirus infektioner
- Picornaviridae infektioner
- Hepatitis, kronisk
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, kronisk
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Antimetabolitter
- Ribavirin
- Peginterferon alfa-2b
Andre undersøgelses-id-numre
- P05632
- BR 002-07
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hepatitis C, kronisk
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsTrukket tilbageKronisk hepatitis C virusinfektionIsrael
-
Hadassah Medical OrganizationUkendtKronisk hepatitis C virusinfektionIsrael
-
Beni-Suef UniversityAfsluttetKronisk hepatitis C virusinfektionEgypten
-
Trek Therapeutics, PBCAfsluttetKronisk hepatitis C | Hepatitis C genotype 1 | Hepatitis C (HCV) | Hepatitis C viral infektionForenede Stater, New Zealand
-
Trek Therapeutics, PBCAfsluttetKronisk hepatitis C | Hepatitis C (HCV) | Hepatitis C genotype 4 | Hepatitis C viral infektionForenede Stater
-
Tripep ABInovio PharmaceuticalsUkendtKronisk hepatitis C virusinfektionSverige
-
Humanity and Health Research CentreBeijing 302 HospitalAfsluttetKronisk hepatitis C-infektionKina
-
AbbVieAfsluttetKronisk hepatitis C | Hepatitis C (HCV) | Hepatitis C genotype 1a
-
AbbVie (prior sponsor, Abbott)AfsluttetKronisk hepatitis C | Hepatitis C genotype 1 | Hepatitis C (HCV)Forenede Stater, Australien, Canada, Frankrig, Tyskland, New Zealand, Puerto Rico, Spanien, Det Forenede Kongerige
-
AbbVieAfsluttetKronisk hepatitis C | Hepatitis C (HCV) | Hepatitis C genotype 1a
Kliniske forsøg med Peginterferon alfa-2b
-
Third Affiliated Hospital, Sun Yat-Sen UniversityPeking University; Huazhong University of Science and Technology; First People... og andre samarbejdspartnereUkendt
-
Third Affiliated Hospital, Sun Yat-Sen UniversityPeking University; Huazhong University of Science and Technology; First People... og andre samarbejdspartnereUkendtKronisk hepatitis BKina
-
BiocadAfsluttetHepatitis | Hepatitis C | Hepatitis C/ Human Immunodeficiency Virus Co-infektionDen Russiske Føderation
-
Xiamen Amoytop Biotech Co., Ltd.Peking University First HospitalAfsluttet
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)AfsluttetBarndoms kraniopharyngiomForenede Stater
-
Hoffmann-La RocheAfsluttetHepatitis C, kroniskBelgien, Irland, Italien, Det Forenede Kongerige
-
Hoffmann-La RocheAfsluttet
-
Fang WangRekruttering
-
Merck Sharp & Dohme LLCAfsluttetHepatitis C, kronisk
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRekrutteringHepatitis B, kroniskKina